Drug Discovery Research Partner

Pelago Bioscience is a Drug Discovery Research Partner supporting preclinical and clinical drug discovery and development. The core of our service is patented Cellular Thermal Shift Assay (CETSA®). Unlike other solutions on the market today, CETSA® allows the assessment and quantification of target engagement under physiological conditions – without the need to modify the compound or protein.

We offer a range of customized services from target identification and validation studies, MoA studies, lead generation, lead optimization efforts, and drug candidate profiling to translational science and rational biomarker discovery. Our approach is designed to help you make better decisions faster, no matter where you are in the drug discovery process.

Located in Stockholm, Sweden, we support worldwide customer base generating data that can strengthen the target validation and build confidence earlier in your projects through CETSA® and its combination with functional assays and extended proteomics compound profiling (for example post-translational modification analysis and quantitative proteomics).

About Drug Discovery Innovation Programme 2023

Drug Discovery Innovation Programme is an invitation-only and one of the best platforms to learn the latest insights and develop lasting business relationships.

This year’s Drug Discovery Innovation Programme will highlight the challenges discovery pipelines have faced due to COVID-19 and will put a spotlight on thec adoption of technology to finding the solutions.

With over 100+ attendees, learn how modernization in R&D processes is fundamentally changing what the drug discovery research will look like in the next two to five years.

So, join us in 2023 for an in-person experience and 2-days of top-level strategic content and the current scientific insights, networking, and discussions from leading global pharmaceutical R&D executives.

Companies in attendance for 2023 will include Servier Pharmaceuticals, Monte Rosa Therapeutics, University of Oxford, WPD Pharmaceuticals, AISA Therapeutics, Anima Biotech, PDC*line Pharma, Eli Lillly and Company, Symphogen, IRB Barcelona, Axonis Therapeutics, Genentech, Arakis Therapeutics, Johnson & Johnson, Amgen, Revitale Pharma, Progenra Inc, CERo Therapeutics, Merck and much more.

So, why wait? Register with us to learn more!